In summary, GLP-1 agonists do not affect tau phosphatase activity but rather inhibit tau hyperphosphorylation by the activation of Akt-driven GSK-3β inhibition by GLP-1R during AD (Reich and Hölscher, 2022). Here, GCG is linked to Alzheimer disease.